Adjuvant Therapy of Non-Small Cell Lung Cancer

Approximately what percent of the time do you use the following adjuvant non-small cell lung cancer (NSCLC) chemotherapy regimens?

Approximate percentage of the time the following platinum-based chemotherapy regimens for adjuvant treatment of NSCLC are utilized:

When recommending adjuvant chemotherapy for NSCLC, which is your preferred agent?

Would you generally recommend adjuvant chemotherapy for patients with PS 0 or 1 in the following scenarios?

A 60-year-old patient is to receive adjuvant chemotherapy for Stage II adenocarcinoma of the lung. In this setting, how would you compare the following regimens?

A 60-year-old patient is to receive adjuvant chemotherapy for Stage II adenocarcinoma of the lung. In this setting, how would you compare the following regimens?

Neoadjuvant chemotherapy alone for localized NSCLC is a reasonable alternative to postoperative adjuvant therapy alone with regard to overall long-term clinical outcome.

What is the role of erlotinib after resection of Stage II NSCLC in the following?

Would you recommend erlotinib (with or without adjuvant chemotherapy) as postoperative treatment for a 61-year-old woman with Stage II pure bronchoalveolar carcinoma?

RADIANT: A Randomized Phase III Study of Erlotinib with or without Adjuvant Chemotherapy in NSCLC Patients with EGFR-Positive Tumors

What is the role of erlotinib for a never smoker with unresectable NSCLC after definitive chemoradiation therapy?

Cost and reimbursement issues aside, would you consider including bevacizumab as adjuvant treatment for a young, otherwise-healthy, well-informed patient with NSCLC who requests it?

The following questions apply to the planned ECOG-E1505 trial, a Phase III trial randomly assigning patients with resected Stage IB (>4 cm) to IIIA NSCLC to adjuvant chemotherapy alone or adjuvant chemotherapy with 1 year of bevacizumab (see figure below). All histologies are eligible, including squamous cell, and patients can receive 1 of the following 3 chemotherapy regimens:

The following questions apply to the planned ECOG-E1505 trial, a Phase III trial randomly assigning patients with resected Stage IB (>4 cm) to IIIA NSCLC to adjuvant chemotherapy alone or adjuvant chemotherapy with 1 year of bevacizumab (see figure below). All histologies are eligible, including squamous cell, and patients can receive 1 of the following 3 chemotherapy regimens:

Phase III Study of Adjuvant Chemotherapy with or without Bevacizumab for Patients with Completely Resected Stage IB-IIIA NSCLC

Which of the following therapies have you used or would you feel comfortable using with bevacizumab in the treatment of NSCLC?

Which of the following therapies have you used or would you feel comfortable using with bevacizumab in the treatment of NSCLC?